Sparks commentary - Newron Pharmaceuticals

Healthcare

Sparks - Newron Pharmaceuticals

More on this equity
Newron Pharmaceuticals (SIX: NWRN) clears key ENIGMA-TRS 1 recruitment hurdle
Published by Arron Aatkar, PhD

Newron has completed screening for ENIGMA-TRS 1, with 996 patients having entered screening, 411 patients already randomised and sufficient patients still in assessment to support enrolment of at least 600 participants by around mid-October. Top-line results from the primary 12-week efficacy assessment are now expected in Q127, representing an important near-term potential catalyst. The update reduces recruitment execution risk and shifts investor focus to whether evenamide can reproduce its encouraging earlier efficacy and tolerability profile in a large, randomised, placebo-controlled pivotal study.

Latest

Energy & Resources | Comment

bp (LSE: BP) – Ian Tyler appointed chair

Healthcare | Comment

BioVersys (SIX:BIOV) gains FDA Fast Track for BV100

Healthcare | Comment

Oryzon (BME: ORY) – Iadademstat IP position strengthened

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.